Trastuzumab Uses, Side Effects & Warnings -

เว็บไซต์ trastuzumab Scottish Medicines Consortium decisions For trastuzumab · SMC No 92813 Trastuzumab for the treatment of adult patients trastuzumab Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2

trastuzumab On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo,  trastuzumab emtansine continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients  Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available targeted chemotherapies

แบ่งปัน

แบ่งปัน

Link

ปิดแชร์. คัดลอกลิงค์

ดูรายละเอียดทั้งหมด